NCT00352105 · REGISTRY CONDITION SEARCH

Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: COMPLETED
Registry last update: 2012-11-05

RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cisplatin, fluorouracil, and gefitinib together with radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving cisplatin, fluorouracil, and gefitinib together with hyperfractionated radiation therapy and to see how well they work in treating patients with locally advanced head and neck cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Patients Treated With ZD1839 With Chemotherapy and Hyperfractionated Radiation That Had a 1-year Survival

→

outcome · POSTED

Number of Participants With No Local Disease at 1 Year

→

outcome · POSTED

Number of Patients With Greater Than or Equal to Mild (Grade 1) Toxicity

→

outcome · POSTED

Number of Patients With a Complete Response Defined as Complete Disappearance of All Clinically Detectable Tumor.

→

outcome · POSTED

Number of Participants Who Completed 2 Years of Therapy

→

outcome · POSTED

Number of Participants With No Distant Metastatic Disease at 1 Year

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Histologically confirmed primary\* squamous cell carcinoma of the head and neck region, excluding any of the following: * Nasopharynx * Paranasal sinuses * Salivary glands NOTE: \*Primary site must be identified * Locoregionally confined stage III or IV disease * No evidence of nodal disease below the clavicles * No distant hematogenous metastases (M0) PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * WBC \> 3,500/mm³ * Platelet count \> 100,000/mm³ * Creatinine ≤ 2.0 mg/dL * Alkaline phosphatase \< 2 times normal * AST \< 2 times normal * Bilirubin ≤ 2.0 mg/dL * Calcium normal * Not pregnant or nursing * Fertile patients must use effective contraception * Must not be a poor compliance risk for follow-up * No known severe hypersensitivity to gefitinib or any excipients of this drug * No evidence of clinically active interstitial lung disease * Patients with chronic, stable radiographic changes who are asymptomatic are eligible * No unstable or uncontrolled angina, clinically apparent jaundice, or active infection * No history of any other malignancy (except squamous cell or basal cell skin cancer or cervical carcinoma in situ) unless disease free for ≥ 5 years * No other severe, uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) PRIOR CONCURRENT THERAPY: * Recovered from prior oncologic or other major surgery * No prior definitive surgery, radiotherapy, chemotherapy, immunotherapy, or epidermal growth factor receptor inhibitors for head and neck cancer * No investigational drugs within the past 30 days * No concurrent CYP3A4 inducers, including any of the following: * Phenytoin * Carbamazepine * Rifampin * Phenobarbital * Hypericum perforatum (St. John's wort) * Concurrent surgery allowed provided gefitinib is not administered 2 weeks before and 2 weeks after surgery * No concurrent aminoglycoside antibiotics
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

intervention Names
Drug: cisplatin
Drug: fluorouracil
Drug: Iressa
Radiation: hyperfractionated radiation therapy
label
Concurrent Chemotherapy and ZD1839
type
EXPERIMENTAL

interventions

arm Group Labels
Concurrent Chemotherapy and ZD1839
description
20mg/m2/d IV continuous infusion x4 days
name
cisplatin
other Names
CDDP
type
DRUG
arm Group Labels
Concurrent Chemotherapy and ZD1839
description
1000mg.m2/d IV continuous x 4 days
name
fluorouracil
other Names
5FU
type
DRUG
arm Group Labels
Concurrent Chemotherapy and ZD1839
description
250mg/PO qd x 2 years
name
Iressa
other Names
ZD1839
type
DRUG
arm Group Labels
Concurrent Chemotherapy and ZD1839
description
120cGy bid
name
hyperfractionated radiation therapy
type
RADIATION

Study design

allocation

NON_RANDOMIZED

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 60
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
To explore the activity of ZD1839 with chemotherapy and hyperfractionated radiation using 1-year survival
measure
Number of Patients Treated With ZD1839 With Chemotherapy and Hyperfractionated Radiation That Had a 1-year Survival
time Frame
at 1 year after start of treatment
description
1-year distant metastatic disease control in patients with locally advanced squamous cell head and neck cancer. Distant disease means that cancer came back in sites outside of the head and neck.
measure
Number of Participants With No Distant Metastatic Disease at 1 Year
time Frame
1 year

secondary Outcomes

description
Number of Participants with No Local Disease at 1 Year. Local disease means that the cancer came back in the same site.
measure
Number of Participants With No Local Disease at 1 Year
time Frame
at 1 year after start of treatment
description
Any toxicity greater than or equal to Grade 1= mild
measure
Number of Patients With Greater Than or Equal to Mild (Grade 1) Toxicity
time Frame
at 1 year after start of treatment
description
Complete response rate per RECIST Criteria (CTC V3)
measure
Number of Patients With a Complete Response Defined as Complete Disappearance of All Clinically Detectable Tumor.
time Frame
3 years
measure
Number of Participants Who Completed 2 Years of Therapy
time Frame
at 2 years after start of treatment

Full study description

brief Summary: RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cisplatin, fluorouracil, and gefitinib together with radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving cisplatin, fluorouracil, and gefitinib together with hyperfractionated radiation therapy and to see how well they work in treating patients with locally advanced head and neck cancer.
detailed Description: OBJECTIVES: Primary * Explore the activity of cisplatin, fluorouracil, gefitinib, and hyperfractionated radiotherapy, in terms of 1-year survival and 1-year distant metastatic disease control, in patients with locally advanced squamous cell carcinoma of the head and neck. Secondary * Explore the activity of this regimen, in terms of disease-specific survival and local control, in these patients. * Assess the toxicity of this regimen in these patients. * Assess the complete response rate in patients treated with this regimen. * Assess the toxicity and tolerability of long-term maintenance with gefitinib in patients rendered disease free after this treatment regimen. OUTLINE: Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IV continuously over 96 hours and cisplatin IV continuously over 96 hours on days 1-4 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3-6 months. PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-40691e0e98c3ddb425d6
requested nct id
NCT00352105
primary nct id
NCT00352105
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
payload sha256
7adcdb614dc8b974bed394487bb938a4ae5fcccba27838981cfb6a064dc12070
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-40691e0e98c3ddb425d6
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00352105
occurrences
context exact
NCT00352105
end
11
exact text
NCT00352105
start
0
offset unit
unicode_code_points
query cond
Laryngeal Cancer
query disease state id
ds-laryngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
source json pointer
/studies/90/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
c997586574769d77d112708ff3021be19b1ebe12361357822faa52cfb2aa76a0
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-b99aad3026434e85627e
requested nct id
NCT00352105
primary nct id
NCT00352105
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
payload sha256
088cff3693d6899d9ffb42540c365fa58331afad0174c07476acfa1f037abe23
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-b99aad3026434e85627e
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00352105
occurrences
context exact
NCT00352105
end
11
exact text
NCT00352105
start
0
offset unit
unicode_code_points
query cond
Hypopharyngeal Cancer
query disease state id
ds-hypopharyngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
source json pointer
/studies/70/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
c997586574769d77d112708ff3021be19b1ebe12361357822faa52cfb2aa76a0
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice